Response to retreatment with interferon-α plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence

American Journal of Gastroenterology

Volumn 94, Issue 9, 1999, Pages 2487-2495

  Ibarrola, Nieves ^a   Moreno Monteagudo, José A ^a   Sáiz, Margarita ^a,b   García Monzón, Carmelo ^a   Sobrino, Francisco ^a,b   García Buey, Luisa ^a   Lo Iacono, Oreste ^a   Moreno Otero, Ricardo ^a   Martínez Salas, Encarnación ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; ASTHMA; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA REPLICASE; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0033199147     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00437-2     Document Type: Article

References (42)

1. Di Bisceglie A., Goodman Z.D., Ishak K.G., et al. Long-term clinical and histopathological follow-up of chronic postransfusion hepatitis. Hepatology. 14:1991;969-974.
2. Takahashi M., Yamada G., Miyamoto R., et al. Natural course of hepatitis C. Am J Gastroenterol. 88:1993;240-243.
3. Davis G.I., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alfa A multicenter randomized controlled trial . N Engl J Med. 321:1989;1501-1506.
4. Tinè F., Magrin S., Craxi A., et al. Interferon for non-A, non-B chronic hepatitis A meta-analysis of randomized clinical trials . J Hepatol. 13:1991;192-199.
5. Fried M.W., Hoofnagle J.H. Therapy of hepatitis C. Semin Liver Dis. 15:1995;82-91.
6. Romeo R., Pol S., Berthelot P., et al. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med. 121:1994;276-277.
7. Cavalletto L., Chemello L., Casarin C., et al. Late reactivation of chronic hepatitis C after sustained biochemical response to interferon therapy. J Hepatol. 23:(suppl 1):1995;77.
8. Serfaty L., Giral P.H., Loria A., et al. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol. 21:1994;12-17.
9. Enomoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:1996;77-81.
10. Chung R.T., Monto A., Diengstag J.L., et al. NS5A mutations do not predict response to interferon in american patients infected with genotype 1 hepatitis C virus. Gastroenterology. 112:1997;A1244. (abstract).
11. Squadrito G., Leone F., Sartori M., et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology. 113:1997;567-572.
12. Lai M.Y., Lao J.H., Yang P.M., et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 111:1996;1307-1312.
13. Schalm S.W., Hansen B.E., Chemello L., et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European center. J Hepatol. 26:1997;961-966.
14. Tilg H. New insights into the mechanisms of interferon alfa An immunoregulatory and anti-inflammatory cytokine . Gastroenterology. 112:1997;1017-1021.
15. De la Torre J.C., Alarcón B., Martínez-Salas E., et al. Ribavirin cures cells of a persistent infection with foot-and-mouth disease virus in vitro. J Virol. 61:1987;233-235.
16. De la Torre J.C., Martínez-Salas E., Diez J., et al. Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus cell culture. J Virol. 62:1998;2050-2058.
17. Clarke B. Molecular virology of hepatitis C virus. J Gen Virol. 78:1997;2397-2410.
18. Gale M.J., Korth M.J., Tang N.M., et al. Evidence that hepatitis C resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 230:1997;217-227.
19. Lindsay K.L. Therapy of hepatitis C Overview . Hepatology. 26:(suppl 1):1997;71S-77S.
20. Chomczynski P. A reagent for the single step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 115:1993;532-537.
21. Kato N., Hijikata M., Ootsuyama Y., et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 87:1990;9524-9528.
22. Devereux J., Haeberti P., Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucl Acids Res. 12:1984;387-395.
23. Enomoto N., Sakuma I., Asahina Y., et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest. 96:1995;224-230.
24. Martell M., Esteban J.I., Quer J., et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes Quasispecies nature of HCV genome distribution . J Virol. 66:1992;3225-3229.
25. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;897-903.
26. Brillanti S., Miglioli M., Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders Italian experience . J Hepatol. 23:(suppl 2):1995;13-16.
27. Dusheiko G., Main J., Thomas H., et al. Ribavirin treatment for patients with chronic hepatitis C Results of a placebo-controlled study . J Hepatol. 25:1996;591-598.
28. Hoofnagle J.H., Lau D., Conjeevaram H., et al. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepatol. 3:1996;247-252.
29. Reichard O., Yun Z.-B., Sönnerborg A., et al. Hepatitis C viral titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol. 22:1993;1-4.
30. Koskinas J., Tibbs C., Saleh M.G., et al. Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon non-responsive patients. J Med Virol. 45:1995;29-34.
31. McHutchinson J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
32. Davis G.L., Esteban-Mur R., Rustigi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 339:1998;1493-1499.
33. Poynard T., Marcellin P., Lee S., et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
34. Schalm S.W., Brouwer J.T., Chemello L., et al. Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci. 41:(suppl 12):1996;131S-134S.
35. Schvarcz R., Ando Y., Sönnerborg A., et al. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone Swedish experience . J Hepatol. 23:(suppl 2):1995;17-21.
36. Main J. Future studies of combination therapy for chronic hepatitis C Optimizing response rates for each hepatitis C population . J Hepatol. 23:(suppl 2):1995;32-36.
37. Reichard D., Norkrans G., Fryden A., et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group. Lancet. 351:1998;83-87.
38. Fattovich G., Giustina G., Favarato S., et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 24:1996;38-43.
39. Okada Si, Hakahane J., Suzuki H., et al. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viraemic patients. Hepatology. 16:1992;619-624.
40. Pawlotsky J.M., Germanidis G., Neumann A.U., et al. Interferon resistence of hepatitis C virus genotype 1b Relationship to nonstructural 5A gene quasispecies mutations . J Virol. 72:1998;2795-2805.
41. Rispeter K., Lu M., Zibert A., et al. The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element. J Hepatol. 29:1998;352-361.
42. Tanji Y., Kaneko S., Sato H., et al. Phosphorylations of hepatitis C virus-encoded nonstructural protein NS5A. J Virol. 69:1995;3980-3986.